How Much Does Immunotherapy for breast cancer Cost in Italy?
Immunotherapy for breast cancer in Italy averages from $18,000 to $34,000 per course. Costs depend on the specific drug protocols, clinic tier, and the patient's diagnostic profile. In the US, similar treatments cost $105,000 on average. Italy offers savings of approximately 75%. This treatment typically includes specialist consultations, drug administration, and laboratory monitoring.
- Private facility fees: Private clinic courses often range between 15-20% higher in northern medical hubs.
- Specialist consultations: Initial oncology evaluations for immunotherapy typically cost between $280 and $300.
- Remote second opinions: Leading research hospitals provide expert document reviews for approximately $400.
- Comprehensive treatment: Total packages including surgery and systemic therapy may reach $24,500.
Bookimed Expert Insight: Choosing a research-heavy center like San Raffaele in Milan offers exceptional value. Dr. Bianchini Giampaolo at San Raffaele leads immunotherapy research with over 100 clinical trials. Treatment there typically runs about $6,500 to $13,500 per course. This clinic holds IRCCS accreditation from the Italian Ministry of Health. Patients access cutting-edge protocols at significantly lower rates than US university hospitals.
| Italy | Turkey | Austria | |
|---|---|---|---|
| Immunotherapy for breast cancer | ≈ $18,000 | from $8,000 | ≈ $18,000 |
Your Benefits and Guarantees with Bookimed
Transparent Prices & Flexible Installments
No hidden fees – just official clinic prices. Pay at the clinic for Immunotherapy for breast cancer upon arrival and use a flexible installment plan if needed.
Verified Clinics & Doctors Only
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Immunotherapy for breast cancer and have the necessary licenses to serve international patients worldwide.
Free 24/7 Assistance
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Immunotherapy for breast cancer journey.

Your personal Bookimed medical coordinator
- Supports you at every stage
- Helps choose the right clinic and doctor
- Ensures quick and convenient access to information
Discover the Best Immunotherapy for breast cancer Clinics in Italy: 1 Verified Option and Prices
Immunotherapy for breast cancer Overview in Italy
Day 1 - Arrival
- Arrive at the clinic and complete the registration process.
- Meet with your oncologist to discuss the immunotherapy plan.
Day 2 - Pre-Operation
- Undergo a series of medical tests including blood tests.
- Meet with a nutritionist to discuss diet during treatment.
Day 3 - Immunotherapy
- Receive the first dose of immunotherapy in outpatient setting.
- The procedure lasts about 3-4 hours, no anesthesia needed.
Day 4 - Post-Operation
- Follow up with your oncologist to check for side effects.
- Stay in the clinic for monitoring if necessary.
Week 1 to Week 3 - Rehabilitation
- You may return to work after one week if you feel well.
- Engage in light physical activities, if tolerated.
Week 4 to Week 6 - Rehabilitation
- Depending on your condition, you may resume more strenuous activities.
- By week 6, you may start to see the effects of therapy.
Please note that each patient reacts differently to immunotherapy. Therefore, this guide might not perfectly correspond to your individual journey. Always consult with your medical team for personalized information.
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
Our Doctors
View all Doctors
Bianchini Giampaolo
Head of Breast Cancer Group at San Raffaele – Dr. Bianchini has led over 100 clinical trials exploring immunotherapy's role in breast cancer.
- 21 years specializing in breast cancer treatment
- Co-inventor of a patent for personalized drug combinations
- Published 45+ papers on breast cancer therapies
- Former visiting scientist at MD Anderson Cancer Center
Video Stories from Bookimed Patients
Reviews about Bookimed: Discover Patients' Insights
All reviews



Share this content
Anna Leonova
FAQ about Immunotherapy for breast cancer in Italy
How safe is immunotherapy for breast cancer in Italy, and what are the main risks?
Immunotherapy for breast cancer in Italy is highly safe when managed at specialized IRCCS research hospitals or dedicated Breast Units. These centers follow strict Italian Medicines Agency protocols. Safety depends on mandatory pre-treatment PD-L1 testing and weekly blood monitoring to manage immune-related side effects early.
- Specialized supervision: Leading centers like San Raffaele in Milan use multidisciplinary teams and PDTA pathways.
- Monitoring protocols: Weekly blood tests identify early signs of pneumonitis or liver inflammation effectively.
- Mandatory testing: Doctors require PD-L1 testing to ensure treatment suitability and minimize unnecessary risks.
- Common reactions: Fatigue and skin rashes are frequent but usually manageable without stopping therapy.
Bookimed Expert Insight: Italian research hospitals like San Raffaele lead global clinical trials for rare immune disorders. This deep expertise translates to superior safety for breast cancer patients. Their specialists often use custom-designed monitoring methods that catch potential organ inflammation before symptoms even appear.
Patient Consensus: Patients emphasize that side effects like thyroiditis or colitis can occur months after finishing. They recommend having prescribed steroids ready and choosing clinics with extensive immunotherapy experience for better risk management.
What survival or response-rate results can breast-cancer patients expect from immunotherapy in Italy?
Breast cancer patients in Italy eligible for immunotherapy see response rates near 50 percent. For triple-negative breast cancer, combined immunotherapy and chemotherapy achieve a 64.8 percent pathologic complete response. Specialized centers in Milan utilize checkpoint inhibitors to extend median survival for metastatic cases from 16 to 23 months.
- Triple-negative response: Combined treatments reach 64.8 percent response versus 51.2 percent for chemotherapy alone.
- Metastatic survival: Median survival increases to 23 months for PD-L1-positive patients using pembrolizumab protocols.
- Five-year outlook: Long-term survival rates improved from 21 percent to 30 percent since 2017.
- Expert centers: Facilities like San Raffaele lead advanced translational research and immunotherapy clinical trials.
Bookimed Expert Insight: While response rates are promising, the real value in Italy lies in the academic integration. Prof. Dr. Bianchini Giampaolo at San Raffaele leads a dedicated research group for immunotherapy. This connection to clinical trials means patients often access the newest drug combinations before they reach global markets. Italy ranks ninth globally for medical requests, reflecting high confidence in their specialized oncology departments.
Who is eligible for immunotherapy in Italian breast-cancer programs?
Eligibility for breast cancer immunotherapy in Italy requires a Triple-Negative Breast Cancer diagnosis, confirmed by biopsy and specific biomarker testing. The Italian Medicines Agency authorizes treatment for early-stage cases with lymph node involvement and metastatic patients showing positive PD-L1 protein expression levels.
- Tumor subtype: Must be Triple-Negative, lacking estrogen, progesterone, and HER2-positive receptors.
- Metric thresholds: Metastatic cases require a specific PD-L1 Combined Positive Score of 10 or higher.
- Clinical stage: Early-stage tumors over 2 cm qualify for neoadjuvant therapy before surgical intervention.
- Health status: Patients need an ECOG performance status of 0 to 1 for intensive treatment.
Bookimed Expert Insight: Clinical research activity directly impacts access in Italy beyond standard regulations. Leading centers like San Raffaele in Milan combine medical assistance with IRCCS-accredited research. Specialist Dr. Bianchini Giampaolo coordinates over 100 clinical trials and holds patents for identifying drug response. This high-volume research environment allows patients who fail AIFA criteria to access innovative genomic-based therapies through compassionate use programs.
Patient Consensus: Patients emphasize the urgency of early PD-L1 and MSI testing. Practical experience shows younger patients often face fewer exclusions during clinical trial enrollment compared to older individuals with comorbidities.
Who actually prescribes and monitors immunotherapy in Italy—oncologist, hospital, or network?
In Italy, the hospital-based medical oncologist is the authorized professional for prescribing and monitoring immunotherapy. They work within accredited centers to evaluate patients against Italian Medicines Agency (AIFA) criteria. Treatment is strictly hospital-based through multidisciplinary oncology groups rather than private pharmacy-filled prescriptions.
- Oncologist's role: Leads the clinical care pathway and manages medication selection and dosages.
- Hospital authority: Administration occurs only in Ministry of Health or JCI-accredited medical facilities.
- Multidisciplinary teams: Specialists like radiologists and surgeons collaborate within hospital oncology groups.
- Regional networks: Oncology networks ensure standardized care pathways across Italy's regional health systems.
- Regulatory oversight: The Italian Medicines Agency governs drug eligibility and centralized high-cost drug management.
Bookimed Expert Insight: Italian centers like San Raffaele in Milan hold IRCCS status, combining clinical treatment with advanced research. This dual role is crucial for immunotherapy. Surgeons there, like Bianchini Giampaolo, also lead translational research groups. This integration allows patients to access cutting-edge protocols and clinical trials directed by their primary treating oncologists. This level of institutional integration often leads to higher oversight during complex treatments.
How many cycles are given, and what is the on-treatment and recovery timeline?
Immunotherapy for breast cancer in Italy typically involves cycles every 2 to 4 weeks, with most protocols spanning 6 to 12 months. Treatment duration depends on cancer stage and drug response, often administered at research centers like San Raffaele in Milan.
- Cycle duration: Each infusion cycle usually lasts 14 to 28 days.
- Treatment frequency: Patients receive drugs on a single day per cycle.
- Initial recovery: Side effects like fatigue often improve 2 to 3 weeks post-session.
- Long-term timeline: Full stamina recovery often takes 6 to 12 months after completion.
Bookimed Expert Insight: Italian centers like San Raffaele act as major IRCCS research hubs. Dr. Bianchini Giampaolo has managed over 100 clinical trials here. This high trial volume means patients often access the latest combination therapies before they reach smaller clinics. Most patients save around 75% compared to US averages while receiving these academic-grade treatments.
What diagnostic tests and biopsies are done before starting immunotherapy?
Diagnostic protocols for breast cancer immunotherapy include biomarker testing via core needle biopsy to measure PD-L1 expression and MSI/MMR status. Italian oncology centers perform baseline imaging like PET/CT scans and brain MRIs alongside liver, kidney, and thyroid function blood panels to ensure patient safety.
- Biomarker expression: IHC staining measures PD-L1 levels on tumor cells to predict treatment response.
- Genetic profiling: Tests identify Microsatellite Instability (MSI) and Mismatch Repair (MMR) defects in DNA.
- Metastatic screening: CT scans of the chest and abdomen rule out spread before starting.
- Organ health: Mandatory thyroid panels and heart ECHO cardiograms establish necessary baseline function.
Bookimed Expert Insight: Italian research hospitals like San Raffaele emphasize PD-L1 CPS scores over 10 for treatment eligibility. Dr. Bianchini Giampaolo, a lead researcher in Milan, uses these specific patent-based metrics to predict drug success. This high-level specialization often results in more precise patient selection than general oncology protocols.
Patient Consensus: Patients emphasize requesting extra biopsy tissue blocks during initial diagnosis. This prevents delays of 2 to 4 weeks if initial samples prove insufficient for mandatory PD-L1 staining requirements.
How long do international patients need to stay in Italy to complete the first evaluation and start therapy?
International patients typically spend 1 to 3 weeks in Italy for initial breast cancer immunotherapy evaluation and treatment commencement. This timeframe covers multidisciplinary team reviews and personalized biomarker testing. Centers like San Raffaele in Milan require pre-arrival record submission to expedite the on-site process.
- Pre-arrival preparation: Submit pathology and imaging digital records 4 to 6 weeks before traveling.
- Evaluation timeline: Specialists often complete the initial on-site assessment within 2 working days.
- Treatment blocks: Therapy cycles usually occur in 1-week blocks before patients can travel home.
- Legal requirements: Non-EU patients must apply for residence permits for stays exceeding 90 days.
Bookimed Expert Insight: Patients can minimize their stay in Milan by scheduling a teleconsult with specialists like Dr. Bianchini Giampaolo beforehand. Data shows that San Raffaele's status as an IRCCS research hospital provides unique access to translational protocols. This often allows for faster internal biomarker profiling than smaller regional clinics can offer.
Patient Consensus: Travelers emphasize that budget stays of 3 to 6 weeks are safer for non-EU residents. They frequently suggest preparing proof of funds early in case hospital administrative waits exceed initial estimates.



